The Board of Directors of IBL HealthCare Limited (IBLHL) takes pleasure to present before the shareholders', performance review together with the condensed interim financial statements of the Company for the period ended September 30, 2022.
The Directors' report is prepared under section 227 of the Companies Act, 2017, chapter XII clause 34 of Listed Companies (Code of Corporate Governance) Regulations, 2019.
SUMMARY OF FINANCIAL PERFORMANCE
September 30,
2022
2021
(Rupees in Thousand)
Revenue
999,487
812,579
Gross profit
306,059
275,035
Gross profit as a percentage of revenue
30.62%
33.85%
Profit before taxation
114,745
110,262
Profit after taxation
85,165
82,795
PRINCIPAL ACTIVITES & OVERVIEW OF FINANCIAL PERFORMANCE
The principal activities of the Company include marketing, selling and distribution of healthcare & consumer products.
The revenue for the current period remained at Rs. 999.49 million as compared to Rs. 812.58 million for the same period last year i-e, an increase of Rs. 186.9 million (23% growth) despite uncertain socio-economic situation in the country. This increase in revenue is mainly due to awarding of tenders for disposable division and nutrition business. However, significant devaluation in currency, restricted the gross margin of the company to 30.6% as compared to 33.9% last year. This growth in revenue & control over expenditure resulted in after tax profit of the Company Rs. 85.1 million compared to Rs. 82.8 million same period last year.
FUTURE OUTLOOK
The Company is continuously striving to maximize the profitability and growth. We are confident that we can generate increased value for shareholders as well as deliver better products and services to our customers. In accomplishing this, we would like to appreciate the enormous cooperation and support of our sales force, without which we will not be able to achieve these results.
We also take this opportunity to thank our employees for their continuing contribution in the achievement of Company's results.
Chief Executive Officer
Director
October 25, 2022
Karachi
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
IBL HealthCare Ltd. published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2022 05:12:07 UTC.
IBL HealthCare Limited is engaged in marketing, selling and distribution of healthcare products. The Company's product categories include nutrition, health, and wellness, ophthalmic, medical disposables, and pharmaceutical. The nutrition category includes toddlers, baby cereals, medical nutrition, lifestyle nutrition, specialty, and infant formulas. The health and wellness category includes consumer health, and hygiene and safety. The ophthalmic category includes vision care and pharma. The Medical Disposables category consists of renal care, critical care and anesthesia, non-drug, blood transfusion, IV administration, and medical gloves. The Pharmaceutical category consists of various products, such as Seapride, Luxave, Conifa, M-Floxin, Urisolin, Hyplar, Ezcolic, Clariza, and Eprazin. The Company is a subsidiary of The Searle Company Limited and International Brands Limited.
IBL HEALTHCARE LIMITED 
